Yujin Hoshida

Physician researcher in liver diseases

[Yujin Hoshida @HoshidaYujin]

https://t.co/tpoDHSa8Fb

[Yujin Hoshida @HoshidaYujin]

A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity https://t.co/Uy0xYbSk4P

[Yujin Hoshida @HoshidaYujin]

Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development https://t.co/zKVcESxHYp

[massimo iavarone @massimoiava]

A new place to learn to share to increase our knowledge in #liver diseases #cirrhosis #HBV #HCV #ACLF #NASH #NAFLD #AIH #alcohol and #HCC (@bruixj @HoshidaYujin Xin Chen Eli Pikarsky) @AASLDtweets @AASLDPresident

[Yujin Hoshida @HoshidaYujin]

Risk stratification and early detection biomarkers for precision HCC screening https://t.co/PuSeUeiOYe

[Henry E. Chang @HenryEChang]

Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease→https://t.co/bvWHgKNhN4 @onatto108 @BachirTaouli @docamitgs @jmarrero6713 @NDP1001 @HoshidaYujin @ScienceTM #HCC #NAFLD #NASH #LiverTwitter #MedTwitter

[Hepatology Communications @HepCommJournal]

Atorvastatin modulates YAP, AKT, and metallothionein pathways, which are implicated in HCC development, and attenuates a clinical HCC risk gene signature in in vitro models of HCV infection and NAFLD.
#OpenAccess #HCV #NAFLD #LiverTwitter #VisualAbstract
https://t.co/CQvbHHONor

[HEPATOLOGY Journal @HEP_Journal]

#HEP_highlights: FASN-ing HCC’s Therapeutic Belts
🐁 HCC models: Early stage➡️FASN inhibitor 👉⬇️de novo lipogenesis 👉⬇️ tumor burden
Late stage FASN-dependent HCC➡️FASN inhibitor + cabozantinib combination 👉 ⬇️⬇️tumor burden➡️synergistic💊
#LiverTwitter
https://t.co/OsHrLuSN06

[HEPATOLOGY Journal @HEP_Journal]

Single-cell profiling of human CD127+ innate lymphoid cells reveals diverse immune phenotypes in hepatocellular carcinoma
#LiverTwitter
https://t.co/hk6loVvuJF

[HEPATOLOGY Journal @HEP_Journal]

#Aspirin use and risk of #HCC in patients with chronic #hepatitisB with or without #cirrhosis
✅Associated with ⬇️ risks of HCC and liver-associated mortality in adults with CHB
✅Cirrhosis status had a substantial effect
#LiverTwitter
https://t.co/r5kzEaTZ4a

[HEPATOLOGY Journal @HEP_Journal]

Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics
#LiverTwitter @massimoiava @bruixj
https://t.co/Tln0OLbJvf

[HEPATOLOGY Journal @HEP_Journal]

#HEP_Highlights August: What do you say? Let’s check the HNF4α
HNF4α play a key role in hepatic differentiation, and ⬇️activity of HNF4α leads to ⬆️ progression to advanced liver disease, hepatic decompensation, development/mortality of HCC.
#LiverTwitter
https://t.co/xyt3xQ3dyg

[HEPATOLOGY Journal @HEP_Journal]

Tian L et al. Dysregulation of RalA signaling through dual regulatory mechanisms exerts its #oncogenic functions in #hepatocellular carcinoma
#livertwitter
https://t.co/WGha8pxsZh

[HEPATOLOGY Journal @HEP_Journal]

Li H et al. El cGGNBP2 inducido por IL-6 codifica una proteína para promover el crecimiento celular y la metástasis en el #colangiocarcinoma intrahepático
@bruixj @xinchen1969 @HoshidaYujin @massimoiava
#LiverTwitter
https://t.co/EtREqrxJOb

[HEPATOLOGY Journal @HEP_Journal]

Fang Y et al. Integration of #glucose and #cardiolipin anabolism confers radiation resistance of #HCC
#LiverTwitter
https://t.co/f1dUbih9JZ

[HEPATOLOGY Journal @HEP_Journal]

#HEP_Highlights June: Effect of diabetes medications and glycemic control on risk of #HCC in patients with #NAFLD @juanpabloarab @SumeraIlyasMD
✅ Metformin was associated with a ⬇️ risk of HCC
❎ Combination therapy associated with ⬆️ risk
#LiverTwitter
https://t.co/PYrE1gsUoC

[Yujin Hoshida @HoshidaYujin]

Epigenetic scars may increase HCC risk after HCV cure

[HEPATOLOGY Journal @HEP_Journal]

#HEP_Highlights Epigenetic ‘scars’ remain after #HCV cure
✅Significant DNA methylation changes linked with altered expression of immune and apoptosis pathway genes persist despite antiviral treatment
✅Epigenetic agents may have a potential role
https://t.co/ZXQawcYkVB

[Cell Press @CellPressNews]

A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis - read the full article by @HoshidaYujin et al. in @MedCellPress #AACR22 https://t.co/BAxzu5FmIG

[Hepatology Communications @HepCommJournal]

Study demonstrates that combining cfDNA methylation with protein markers is a promising way to detect #cancer in earlier stages. @GABOUALFAl, @superweili, @HoshidaYujin, @RobertGish

[HEPATOLOGY Journal @HEP_Journal]

#HEP_Highlights Surveillance for hepatocellular carcinoma (HCC) development in cirrhotic patients continues to evolve. Singal et al. demonstrate that GALAD’s sensitivity for detection of HCC outperformed AFP in a prospective cohort of cirrhotic patients
https://t.co/yr5jTuchAw